136 related articles for article (PubMed ID: 30677105)
1. The Relevance of Clinical Pharmacology Studies of Basal Insulins to Primary Care.
Reid TS; White J; Meneghini L
J Fam Pract; 2019 Jan; 68(1 Suppl):. PubMed ID: 30677105
[TBL] [Abstract][Full Text] [Related]
2. Understanding how pharmacokinetic and pharmacodynamic differences of basal analog insulins influence clinical practice.
Goldman J; Kapitza C; Pettus J; Heise T
Curr Med Res Opin; 2017 Oct; 33(10):1821-1831. PubMed ID: 28537449
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetic and pharmacodynamic differences of new generation, longer-acting basal insulins: potential implications for clinical practice in type 2 diabetes.
Hompesch M; Patel DK; LaSalle JR; Bolli GB
Postgrad Med; 2019 Mar; 131(2):117-128. PubMed ID: 30691343
[TBL] [Abstract][Full Text] [Related]
4. How pharmacokinetic and pharmacodynamic principles pave the way for optimal basal insulin therapy in type 2 diabetes.
Arnolds S; Kuglin B; Kapitza C; Heise T
Int J Clin Pract; 2010 Sep; 64(10):1415-24. PubMed ID: 20618882
[TBL] [Abstract][Full Text] [Related]
5. Variability of glucose-lowering effect as a limiting factor in optimizing basal insulin therapy: a review.
Vora J; Heise T
Diabetes Obes Metab; 2013 Aug; 15(8):701-12. PubMed ID: 23451796
[TBL] [Abstract][Full Text] [Related]
6. Leveraging Clinical Pharmacology Data to Assess Biosimilarity and Interchangeability of Insulin Products.
Vaidyanathan J; Wang YC; Tran D; Seo SK
Clin Pharmacol Ther; 2023 Apr; 113(4):794-802. PubMed ID: 36052570
[TBL] [Abstract][Full Text] [Related]
7. Design of non-standard insulin analogs for the treatment of diabetes mellitus.
Pandyarajan V; Weiss MA
Curr Diab Rep; 2012 Dec; 12(6):697-704. PubMed ID: 22983891
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics and pharmacodynamics of basal insulins.
Porcellati F; Bolli GB; Fanelli CG
Diabetes Technol Ther; 2011 Jun; 13 Suppl 1():S15-24. PubMed ID: 21668333
[TBL] [Abstract][Full Text] [Related]
9. Will the next generation of basal insulins offer clinical advantages?
Garber AJ
Diabetes Obes Metab; 2014 Jun; 16(6):483-91. PubMed ID: 24118819
[TBL] [Abstract][Full Text] [Related]
10. Degludec: a novel basal insulin.
Kalra S; Baruah MP; Niazi AK
Recent Pat Endocr Metab Immune Drug Discov; 2012 Jan; 6(1):18-23. PubMed ID: 22280221
[TBL] [Abstract][Full Text] [Related]
11. Insulin degludec: a novel basal insulin analogue.
Goldman-Levine JD; Patel DK; Schnee DM
Ann Pharmacother; 2013 Feb; 47(2):269-77. PubMed ID: 23386075
[TBL] [Abstract][Full Text] [Related]
12. The role of the new basal insulin analogs in addressing unmet clinical needs in people with type 1 and type 2 diabetes.
Lajara R; Cengiz E; Tanenberg RJ
Curr Med Res Opin; 2017 Jun; 33(6):1045-1055. PubMed ID: 28277867
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics and pharmacodynamics of insulin glargine 300 U/mL in the treatment of diabetes and their clinical relevance.
Owens DR
Expert Opin Drug Metab Toxicol; 2016 Aug; 12(8):977-87. PubMed ID: 27453980
[TBL] [Abstract][Full Text] [Related]
14. Application of PK/PD modeling and simulation to dosing regimen optimization of high-dose human regular U-500 insulin.
de la Peña A; Ma X; Reddy S; Ovalle F; Bergenstal RM; Jackson JA
J Diabetes Sci Technol; 2014 Jul; 8(4):821-9. PubMed ID: 24876428
[TBL] [Abstract][Full Text] [Related]
15. Comparison of the pharmacokinetic and pharmacodynamic profiles of insulin degludec and insulin glargine.
Heise T; Hövelmann U; Nosek L; Hermanski L; Bøttcher SG; Haahr H
Expert Opin Drug Metab Toxicol; 2015; 11(8):1193-201. PubMed ID: 26086190
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics and pharmacodynamics of insulin glargine given in the evening as compared with in the morning in type 2 diabetes.
Porcellati F; Lucidi P; Cioli P; Candeloro P; Marinelli Andreoli A; Marzotti S; Ambrogi M; Bolli GB; Fanelli CG
Diabetes Care; 2015 Mar; 38(3):503-12. PubMed ID: 25524950
[TBL] [Abstract][Full Text] [Related]
17. Comparison of the pharmacokinetic and pharmacodynamic profiles of biphasic insulin aspart 50 and 30 in patients with type 2 diabetes mellitus: a single-center, randomized, double-blind, two-period, crossover trial in Japan.
Hirao K; Maeda H; Urata S; Takisawa Y; Hirao S; Sasako T; Sasaki T
Clin Ther; 2007 May; 29(5):927-934. PubMed ID: 17697911
[TBL] [Abstract][Full Text] [Related]
18. Multinational Consensus: Insulin Initiation with Insulin Degludec/Aspart (IDegAsp).
Kalra S; Atkin S; Cervera A; Das AK; Demir O; Demir T; Fariduddin M; Vo KT; Ku BJ; Kumar A; Latif ZA; Malek R; Matawaran BJ; Mehta R; Tran NQ; Panelo A; Ruder S; Saldana JR; Shaikh KA; Shakya A; Shrestha D; Unnikrishnan AG
Adv Ther; 2018 Jul; 35(7):928-936. PubMed ID: 29796928
[TBL] [Abstract][Full Text] [Related]
19. The Effect of BMI on Pharmacokinetic and Pharmacodynamic Parameters of Insulin Degludec: Results from an Euglycemic Glucose Clamp Study.
Li T; Liu H; Li S; Yu H; Li J; Tan H; Yu Y
Clin Pharmacokinet; 2023 Mar; 62(3):449-456. PubMed ID: 36738401
[TBL] [Abstract][Full Text] [Related]
20. [New generation of insulins: glargine U300. Summary of clinical evidence].
Musso C; Capurro L; Mingote E; Forti L; Guaita MS
Medicina (B Aires); 2019; 79(4):241-250. PubMed ID: 31487242
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
